Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2251 - 2275 of 15556 in total
Ferric pyrophosphate citrate is a soluble iron replacement product. Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma. The ferric ion is strongly complexed by pyrophosphate and citrate. FPC is categorized in...
Approved
Investigational
Matched Iupac: … tetrairon(3+) bis((phosphonooxy)phosphonic acid) tris(2-hydroxypropane-1,2,3-tricarboxylate) (hydrogen …
Matched Description: … The ferric ion is strongly complexed by pyrophosphate and citrate. ... Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation …
Matched Categories: … Enzymes and Coenzymes …
Tofersen is under an intrathecally administered antisense oligonucleotide targeting the mutated SOD1 gene that causes amyotrophic lateral sclerosis (ALS). Although there were various causes of ALS, 2% of ALS cases are due to SOD1 mutations, with more than 200 SOD1 mutations documented.[A259028,A259033] Tofersen was granted accelerated approval from the FDA...
Approved
Investigational
Matched Description: … [A259023] However, it could potentially be due to the short timeframe of tofersen treatment, and more ... [L46133] Tofersen demonstrated efficacy in reducing the concentration of SOD1 in CSF and of neurofilament …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
An ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists).
Approved
Investigational
Matched Iupac: … 3,3-diethyl-1-[(4S,7R)-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),2,9,12,14 …
Matched Description: … It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors …
Matched Categories: … Ergot Alkaloids and Derivatives ... Genito Urinary System and Sex Hormones …
Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
Approved
Investigational
Matched Iupac: … N-(4-{4-methyl-3,5,9-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(14),2(6),3,10,12-pentaene-9-carbonyl}phenyl …
Matched Description: … Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). …
Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. First approved by the FDA on September 15, 2023, momelotinib is used to treat myelofibrosis. Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells,...
Approved
Investigational
Matched Description: … Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. ... Clinical manifestations of MF include anemia and thrombocytosis. ... MF includes primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.[A244195, A244200, A244205] Monoclonal antibodies for B cell depletion rely on their binding affinity and ability to clear bound cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), mediated by...
Approved
Investigational
Matched Description: … and autoimmune conditions. ... CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers ... A244195, A244200, A244205] Monoclonal antibodies for B cell depletion rely on their binding affinity and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic,...
Approved
Investigational
Matched Description: … Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients ... [L14315] Given its mechanism of action and good safety profile, it may prove useful in the treatment …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV)...
Approved
Investigational
Matched Description: … It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. ... There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by Indevus Pharmaceutical Inc. and...
Approved
Matched Description: … [L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes ... [L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007 …
Matched Categories: … trospium and analgesics ... Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb. Nivolumab was...
Approved
Matched Description: … [L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region ... with the mutation _S228P_ for additional stability and reduced variability. …
Matched Categories: … nivolumab and relatlimab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Ammonia N 13 Injection, USP is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. The active ingredient, [13N] ammonia, has the molecular formula of 13NH3 with a molecular weight of 16.02. Ammonia N 13 Injection, USP is used for imaging...
Approved
Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by the FDA...
Approved
Investigational
Matched Description: … tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive ... disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and ... Thyroid eye disease is a potentially debilitating complication of Graves' Disease involving inflammation and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. It works by blocking...
Approved
Investigational
Matched Description: … Ravulizumab is a potent and selective complement 5 (C5) inhibitor. ... atypical hemolytic uremic syndrome in children and adults. ... was engineered from [eculizumab], another complement inhibitor, to increase the duration of action and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073]. Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073]....
Approved
Investigational
Matched Description: … S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) [FDA Label, F2356]. ... Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) ... antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan...
Approved
Matched Description: … in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and ... chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other...
Approved
Investigational
Matched Description: … as well as its short duration of action and easy reversibility provide advantages over, or alternatives ... Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination …
Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
Approved
Matched Categories: … Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of developing febrile neutropenia...
Approved
Matched Description: … pharmacokinetic profile and conditions of use. ... than 20% in many readily used chemotherapy regimens,[A248855] infections pose risks of hospitalization and ... Pelmeg, Udenyca, Ziextenzo, Grasustek, Fylnetra, Stimufend) by Health Canada, European Union (EU), and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis. By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated...
Approved
Investigational
Matched Description: … It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and ... [A262919] Tislelizumab is generally well tolerated with manageable and mild-to-moderate adverse effects …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. Other monoclonal...
Approved
Investigational
Matched Description: … By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune ... death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and ... [L45603] Other monoclonal antibodies that block PD-1 include [pembrolizumab], [nivolumab] and [cemiplimab …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Chagas disease, caused by a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and humans in the Americas. It is commonly known as American Trypanosomiasis. The CDC estimates that approximately 8 million people in Central America, South America, and Mexico are infected with T. cruzi, without...
Approved
Investigational
Matched Iupac: … 3-methyl-4-[(E)-[(5-nitrofuran-2-yl)methylidene]amino]-1lambda6-thiomorpholine-1,1-dione …
Matched Description: … a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and ... L15366] The CDC estimates that approximately 8 million people in Central America, South America, and
Matched Categories: … Agents Against Leishmaniasis and Trypanosomiasis ... Antiparasitic Products, Insecticides and Repellents …
Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough...
Approved
Investigational
Matched Description: … , L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and ... Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib...
Approved
Matched Iupac: … 4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one …
Matched Description: … Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and ... [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health ... [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US. The pathophysiology of this disease is mainly attributed to the deficiency of the CD55 protein, which is the main regulator of the complement...
Approved
Investigational
Matched Description: … cleavage of C3 and C5 respectively into immunoreactive peptides C3a and C5a. ... Under normal circumstances, CD55 inhibits the activity of C3 and C5 convertases, thus preventing the ... resulting in paroxysmal nocturnal hemoglobinuria and complement-mediated autoimmune hemolysis that are …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Approved
Vet approved
Displaying drugs 2251 - 2275 of 15556 in total